Common Contracts
3 similar null contracts by Roivant Sciences Ltd.
MEMORANDUM OF UNDERSTANDING FOR STRATEGIC ALLIANCERoivant Sciences Ltd. • September 6th, 2019 • Pharmaceutical preparations • New York
This non-binding memorandum of understanding (“MoU”), dated September 6, 2019, is entered into between Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo”) and Roivant Sciences Ltd. (“Roivant” and, together with Sumitomo, each a “Party” and together the “Parties”) to summarize certain material terms for the preparation of one or more definitive agreements (the “Strategic Alliance Agreements”) to be negotiated between the Parties related to a strategic alliance between the Parties. The strategic alliance is contemplated to involve the acquisition by Sumitomo of the ownership interest of Roivant in certain subsidiaries of Roivant, an investment by Sumitomo in Roivant, and ongoing strategic cooperation between the Parties. The Parties acknowledge that the Strategic Alliance Agreements will include additional terms, some of which will be material to the Parties, that do not appear in this MoU. The Parties acknowledge and agree that except as set forth in Sections 13-18 below, this MoU does not
MEMORANDUM OF UNDERSTANDING FOR STRATEGIC ALLIANCERoivant Sciences Ltd. • September 6th, 2019 • Pharmaceutical preparations • New York
This non-binding memorandum of understanding (“MoU”), dated September 6, 2019, is entered into between Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo”) and Roivant Sciences Ltd. (“Roivant” and, together with Sumitomo, each a “Party” and together the “Parties”) to summarize certain material terms for the preparation of one or more definitive agreements (the “Strategic Alliance Agreements”) to be negotiated between the Parties related to a strategic alliance between the Parties. The strategic alliance is contemplated to involve the acquisition by Sumitomo of the ownership interest of Roivant in certain subsidiaries of Roivant, an investment by Sumitomo in Roivant, and ongoing strategic cooperation between the Parties. The Parties acknowledge that the Strategic Alliance Agreements will include additional terms, some of which will be material to the Parties, that do not appear in this MoU. The Parties acknowledge and agree that except as set forth in Sections 13-18 below, this MoU does not
MEMORANDUM OF UNDERSTANDING FOR STRATEGIC ALLIANCERoivant Sciences Ltd. • September 6th, 2019 • Pharmaceutical preparations • New York
This non-binding memorandum of understanding (“MoU”), dated September 6, 2019, is entered into between Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo”) and Roivant Sciences Ltd. (“Roivant” and, together with Sumitomo, each a “Party” and together the “Parties”) to summarize certain material terms for the preparation of one or more definitive agreements (the “Strategic Alliance Agreements”) to be negotiated between the Parties related to a strategic alliance between the Parties. The strategic alliance is contemplated to involve the acquisition by Sumitomo of the ownership interest of Roivant in certain subsidiaries of Roivant, an investment by Sumitomo in Roivant, and ongoing strategic cooperation between the Parties. The Parties acknowledge that the Strategic Alliance Agreements will include additional terms, some of which will be material to the Parties, that do not appear in this MoU. The Parties acknowledge and agree that except as set forth in Sections 13-18 below, this MoU does not
